BIXT — BIOXYTRAN, INC

—
OTC · Health Care · Pharmaceuticals · CIK 1445815 ·
Last close
$0.02
Market Cap
$2.66M
52W High
$0.09
52W Low
$0.02
ADV30
62,885
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -660,180 -619,929 333,393 177,384 5,274,697
Mar 2026 0 — -1,935,161 -2,068,989 615,253 463,047 5,010,121
Dec 2025 0 — -610,232 -522,155 658,552 509,914 3,249,894
Sep 2025 0 — -500,241 -282,726 156,294 14,499 3,060,937

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-874,319
Investing CF
$-29,033
Financing CF
$1,077,592
CapEx
$-29,033
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.03
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-23,733,164
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-3,257,676
Pretax Income TTM
$-3,493,799
Interest Exp TTM
$236,123
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -1,854,053 -2,123,077 658,552 3,249,894 -2,591,342 -526,455
Dec 2024 0 -2,231,018 -2,366,681 138,694 1,930,642 -1,791,948 -381,316
Dec 2023 0 -3,808,497 -4,472,525 139,382 3,244,238 -2,423,970 -775,375
Dec 2022 0 -2,440,185 -2,473,134 370,936 3,667,911 -2,706,347 -1,803,670

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-3,493,797
OpCashFlow TTM
—
Assets (Latest)
$333,393
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
ERNA Ernexa Therapeutics Inc. $2.66M $1.63 —
NXTS Nexentis Technologies Inc. $2.65M $1.82 —
MBIO MUSTANG BIO, INC. $2.63M $0.39 —
EOCN EoCene Ltd. $2.63M $2.46 —
PPBT PURPLE BIOTECH LTD. $2.78M $1.71 —

News headlines (Yahoo Finance, 1h cache)

Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products
2026-11-16 12:00 · Yahoo
Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar
2026-10-19 11:00 · Yahoo
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial
2026-08-11 11:00 · Yahoo
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
2026-05-29 12:03 · Yahoo
Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets
2026-11-04 12:00 · Yahoo
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
2026-08-04 11:00 · Yahoo
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
2026-07-29 11:00 · Yahoo
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
2026-03-20 13:05 · Yahoo
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
2026-03-04 20:40 · Yahoo
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
2026-03-02 16:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.